Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
Sage Therapeutics, Inc. (NASDAQ: SAGE) has announced that it will host a live webcast on Tuesday, October 29, 2024, at 4:30 p.m. ET. The purpose of this webcast is to review the company's third quarter 2024 financial results and provide updates on recent business activities. Investors and interested parties can access the webcast through the Investor page of Sage's website at investor.sagerx.com. For those unable to attend the live event, a replay will be made available and archived for up to 30 days following the webcast's completion.
Sage Therapeutics, Inc. (NASDAQ: SAGE) ha annunciato che ospiterà un webcast dal vivo il martedì 29 ottobre 2024, alle 16:30 ET. Lo scopo di questo webcast è di esaminare i risultati finanziari del terzo trimestre 2024 e fornire aggiornamenti sulle recenti attività aziendali. Gli investitori e le parti interessate possono accedere al webcast tramite la pagina per gli investitori del sito web di Sage all'indirizzo investor.sagerx.com. Per coloro che non possono partecipare all'evento dal vivo, sarà disponibile una registrazione archiviata per un periodo massimo di 30 giorni dopo il completamento del webcast.
Sage Therapeutics, Inc. (NASDAQ: SAGE) ha anunciado que realizará una transmisión en vivo el martes 29 de octubre de 2024, a las 4:30 p.m. ET. El propósito de esta transmisión es revisar los resultados financieros del tercer trimestre de 2024 y proporcionar actualizaciones sobre las actividades comerciales recientes. Los inversores y partes interesadas pueden acceder a la transmisión a través de la página para inversores del sitio web de Sage en investor.sagerx.com. Para quienes no puedan asistir al evento en vivo, se pondrá a disposición una repetición y se archivará durante un máximo de 30 días después de la finalización de la transmisión.
Sage Therapeutics, Inc. (NASDAQ: SAGE)는 2024년 10월 29일 화요일 오후 4시 30분 ET에 라이브 웹캐스트를 개최한다고 발표했습니다. 이번 웹캐스트의 목적은 2024년 3분기 경영 결과를 검토하고 최근 비즈니스 활동에 대한 업데이트를 제공하는 것입니다. 투자자와 이해관계자는 Sage 웹사이트의 투자자 페이지(investor.sagerx.com)를 통해 웹캐스트에 접근할 수 있습니다. 라이브 이벤트에 참석할 수 없는 분들을 위해, 웹캐스트 완료 후 최대 30일 동안 재방송이 제공될 예정입니다.
Sage Therapeutics, Inc. (NASDAQ: SAGE) a annoncé qu'elle organisera un webcast en direct le mardi 29 octobre 2024, à 16h30 ET. Le but de ce webcast est de passer en revue les résultats financiers du troisième trimestre 2024 et de fournir des mises à jour sur les activités commerciales récentes. Les investisseurs et les parties intéressées peuvent accéder au webcast via la page Investisseur du site de Sage à l'adresse investor.sagerx.com. Pour ceux qui ne peuvent pas assister à l'événement en direct, une rediffusion sera disponible et archivée pendant un maximum de 30 jours après la fin du webcast.
Sage Therapeutics, Inc. (NASDAQ: SAGE) hat angekündigt, dass am Dienstag, den 29. Oktober 2024, um 16:30 Uhr ET ein Live-Webcast stattfinden wird. Ziel dieses Webcasts ist es, die Finanzresultate des dritten Quartals 2024 zu überprüfen und Updates zu den aktuellen Geschäftstätigkeiten zu geben. Investoren und interessierte Parteien können über die Investoren-Seite der Sage-Website auf den Webcast zugreifen unter investor.sagerx.com. Für diejenigen, die an der Live-Veranstaltung nicht teilnehmen können, wird eine Wiederholung bereitgestellt und bis zu 30 Tage nach Abschluss des Webcasts archiviert.
- None.
- None.
The webcast can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.
About Sage Therapeutics
Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241013696613/en/
Investor
Katie Plante
+1 978 968 9099
Katie.Plante@sagerx.com
Media
Matthew Henson
+1 917 930 7147
Matthew.Henson@sagerx.com
Source: Sage Therapeutics, Inc.
FAQ
When will Sage Therapeutics (SAGE) report its Q3 2024 financial results?
How can investors access Sage Therapeutics' (SAGE) Q3 2024 earnings webcast?
Will there be a replay available for Sage Therapeutics' (SAGE) Q3 2024 earnings webcast?
